United Therapeutics CorpNASDAQ:UTHR
- LAST PRICE329.1600
- TODAY'S CHANGE (%)0.4900 (0.1491%)
- Bid / Lots316.0000/ 1
- Ask / Lots334.0200/ 2
- Open / Previous Close328.9100 / 328.6700
- Day Range
- 52 Week Range
- Volume300,407
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | UTHR |
|---|---|---|
| 02:26 ET | 676 | 328.23 |
| 02:27 ET | 100 | 328.24 |
| 02:29 ET | 2942 | 328.51 |
| 02:42 ET | 100 | 329.11 |
| 02:47 ET | 100 | 329.215 |
| 02:49 ET | 100 | 329.35 |
| 02:51 ET | 3202 | 329.55 |
| 02:54 ET | 600 | 329.72 |
| 02:58 ET | 220 | 329.795 |
| 03:02 ET | 910 | 329.7754 |
| 03:05 ET | 300 | 329.93 |
| 03:09 ET | 600 | 330.3375 |
| 03:12 ET | 541 | 330.295 |
| 03:14 ET | 100 | 330.29 |
| 03:18 ET | 484 | 330.315 |
| 03:20 ET | 800 | 330.58 |
| 03:21 ET | 1268 | 330.665 |
| 03:23 ET | 100 | 330.6145 |
| 03:25 ET | 769 | 330.32 |
| 03:27 ET | 237 | 330.39 |
| 03:32 ET | 100 | 330.23 |
| 03:34 ET | 1200 | 330.64 |
| 03:36 ET | 1310 | 330.7 |
| 03:39 ET | 1487 | 329.93 |
| 03:41 ET | 1430 | 329.3 |
| 03:45 ET | 500 | 328.89 |
| 03:48 ET | 1100 | 329.39 |
| 03:50 ET | 300 | 329.37 |
| 03:52 ET | 1687 | 329.68 |
| 03:54 ET | 600 | 329.23 |
| 03:56 ET | 2442 | 328.86 |
| 03:57 ET | 3462 | 329.0003 |
| 03:59 ET | 7158 | 329.16 |
Jul 11, 2024
DJ United Therapeutics Is Maintained at Buy by TD Cowen, from 8:05AM ET on Thursday Jul 11, 2024 by Dow Jones
8:05AM ET on Thursday Jul 11, 2024 by Dow JonesDJ United Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley, from 5:37AM ET on Thursday Jul 11, 2024 by Dow Jones
5:37AM ET on Thursday Jul 11, 2024 by Dow Jones
Jul 10, 2024
Jul 8, 2024
DJ United Therapeutics Is Maintained at Buy by UBS, from 12:05PM ET on Monday Jul 08, 2024 by Dow Jones
12:05PM ET on Monday Jul 08, 2024 by Dow Jones
Jun 27, 2024
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors, from 7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
United Therapeutics Corp | 14.7B | 15.6x | +8.22% |
Biomarin Pharmaceutical Inc | 16.1B | 78.6x | --- |
Neurocrine Biosciences Inc | 14.6B | 40.0x | +62.04% |
Beigene Ltd | 17.0B | -20.4x | --- |
Medpace Holdings Inc | 13.5B | 42.9x | +35.10% |
Exact Sciences Corp | 9.1B | -35.3x | --- |
Company Information
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Contact Information
- Headquarters
- 1000 SPRING STSILVER SPRING, MD, United States 20910
- Phone
- 301-608-9292
- Fax
- 301-608-9291
Executives
- Chairman of the Board, Chief Executive Officer
- Martine Rothblatt
- President, Chief Operating Officer
- Michael Benkowitz
- Lead Independent Vice Chairman of the Board
- Christopher Patusky
- Chief Financial Officer, Treasurer
- James Edgemond
- Executive Vice President, General Counsel, Corporate Secretary
- Paul Mahon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.7B |
|---|---|
Revenue (TTM) | $2.5B |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.56 |
EPS | $21.13 |
Book Value | $127.23 |
P/E Ratio | 15.6x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | 13.3x |
Operating Margin | 50.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
